Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$24.98 USD
+0.81 (3.35%)
Updated Aug 23, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
CHGCY 24.98 +0.81(3.35%)
Will CHGCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHGCY
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Other News for CHGCY
Invesco Developing Markets Fund Q2 2024 Quarterly Review
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript
Roche receives FDA clearance on its digital pathology solution for diagnostic use
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing